

Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats

Ernest Adeghate & Abdul Samad Ponery

Department of Anatomy, Faculty of Medicine and Health Sciences, United Arab Emirates University, P.O. Box 17666, Al Ain, UNITED ARAB EMIRATES

Correspondence to: Ernest Adeghate MD, PhD
Department of Anatomy
Faculty of Medicine and Health Sciences
United Arab Emirates University
P O Box 17666
Al Ain, UNITED ARAB EMIRATES
TEL: 971-3-7039496 FAX: 971-3-7672033
EMAIL: eadeghate@uaeu.ac.ae

Submitted: February 20, 2004

Accepted: February 22, 2004

Key words: **insulin; diabetes mellitus; ipamorelin; radioimmunoassay; pancreas adrenergic receptor antagonists; cholinergic receptor antagonist**

Neuroendocrinol Lett 2004; 25(6):403-406 NEL250604A01 Copyright © Neuroendocrinology Letters www.nel.edu

Abstract

OBJECTIVE: To examine the effect of ipamorelin (IPA), a novel pentapeptide with a strong growth hormone releasing potency, on insulin secretion from pancreatic tissue fragments of normal and diabetic rats.

MATERIALS AND METHODS: Diabetes mellitus was induced by streptozotocin (60 mg kg⁻¹). Four weeks after the induction of diabetes, pancreatic tissue fragments of normal and diabetic rats were removed and incubated with different concentrations (10⁻¹²-10⁻⁶ M) of IPA. Insulin release from the pancreas was measured by radioimmunoassay.

RESULTS: Ipamorelin evoked significant (p<0.04) increases in insulin secretion from the pancreas of normal and diabetic rats. Either diltiazem or yohimbine or propranolol or a combination of atropine, propranolol and yohimbine inhibited IPA-evoked insulin secretion significantly (p<0.03) from the pancreas of normal and diabetic rats. Atropine caused a significant (p<0.007) reduction in the IPA-induced insulin secretion in diabetic but not in normal rats.

CONCLUSION: IPA stimulates insulin release through the calcium channel and the adrenergic receptor pathways. This is the first study to examine the effect of ipamorelin on insulin secretion in the pancreas.

Introduction

Ipamorelin (IPA) is a newly discovered pentapeptide with a strong potency for growth hormone release in vivo and in vitro [1]. The administration of IPA significantly increases body weight in rats [2, 3]. IPA can also cause an increase in bone mineral content in rats [4] and induce an increased serum leptin level and food intake in growth hormone-intact mice [5]. For example

IPA, when given at 100 microg/kg three times daily, can counteract glucocorticoid-induced decrease in muscle strength and bone formation in rat [6]. The physiological role of IPA is similar to those described for ghrelin [7-8]. In fact, ghrelin has been shown to regulate insulin release from the pancreas of normal and diabetic rats [7]. IPA increases the percentage of somatotroph cells,

without modifying the ratio of strongly/weakly immunostained GH cells. Moreover, IPA can increase intracellular GH content suggesting that IPA is able to exert a dynamic control on the somatotroph population and on GH hormone content of rat [9].

All of the above properties of IPA indicate that IPA may have a potential role for the treatment of growth retardation and associated illnesses. Since insulin is important in the control of body weight and normal growth, it is pertinent to examine the role of IPA on insulin secretion. The aim of this study was to examine whether IPA has a role in the regulation of insulin secretion from the pancreas of normal and diabetic rats. The study was also designed to examine the mechanisms by which IPA influences insulin secretion.

Materials and Methods

Experimental animals and induction of diabetes mellitus

Twelve-week old male Wistar rats weighing approximately 250 grams were used in this study. The rats were divided into two groups, streptozotocin (STZ)-induced diabetics ($n = 8$) and age-matched controls ($n = 8$). Diabetes mellitus was induced by a single dose of STZ at 60 mg kg^{-1} according to a previously described method [10]. Four weeks from the date of induction of diabetes, all rats from both groups were sacrificed under chloral hydrate general anesthesia (7% chloral hydrate 6-ml kg^{-1} of body weight, injected intraperitoneally). The abdomen was opened and the pancreas was expeditiously removed and placed in ice-cold Krebs buffer (KB). The study was in line with the guidelines of the Animal Ethics Committee, FMHS, UAE University, Al Ain, United Arab Emirates.

Determination of insulin release from pancreatic fragments of normal and diabetic rats

The pancreata of normal and diabetic rats were cut into small pieces and trimmed free of adherent fat and connective tissue and minced into small fragments ($0.5\text{--}1 \text{ mm}^3$). The pancreatic tissue fragments were placed in 2 ml glass vials containing 1 ml of KB and pre-incubated for 30 min in a waterbath at 37°C , in order to wash away any hormone due to cutting of the tissues. Immediately after the pre-incubation step the KB solution was carefully drained and the specimens were subsequently incubated for 1 h with different concentrations (10^{-12} – 10^{-6} M) of ipamorelin (IPA) or with IPA (10^{-9} M) and atropine (10^{-6} M); IPA (10^{-9} M) and yohimbine (10^{-6} M); IPA (10^{-9} M) and propranolol (10^{-6} M), IPA (10^{-9} M) and diltiazem (10^{-6} M) and IPA (10^{-9} M) and atropine and yohimbine and propranolol (10^{-6} M). In the control experiments, the isolated pancreatic fragments were incubated in KB solution alone for the same period. The vials were gassed with a mixture of 95% oxygen and 5% carbon dioxide every 3 min. At the end of the incubation period the pancreatic tissue fragments were removed, blotted, weighed and the effluent stored at -20°C for insulin radioimmunoassay.

Radioimmunoassay

The insulin content of the effluent was determined by using the protocol provided by Linco® (St. Charles, MO, USA), the vendor of the insulin radioimmunoassay kit used in this study. All test samples and controls were assayed in duplicates. A volume of $100 \mu\text{l}$ of either calibrators, controls or test samples were pipetted into previously labelled tubes followed by $100 \mu\text{l}$ of [^{125}I] I-Insulin. Each tube was vortexed and incubated for 24 h at room temperature. After the incubation period, the tubes were centrifuged and decanted for 3 min and radioactivity was counted for 1 min using gamma counter (Beckman, Fullerton, CA, USA). Results were analyzed by using a Beckman Immunofit RIA analysis software version 2.00 and values were expressed in ng ml^{-1} ($100 \text{ mg tissue}^{-1}$). Pancreatic tissue fragments were homogenized in KB solution to determine pancreatic insulin content of normal and diabetic rats.

Chemicals and Statistical analysis

Ipamorelin (Catalogue # SC1329) was obtained from Neosystem® (Strasbourg, France). All other chemicals were purchased from Sigma (Poole, UK) unless otherwise specified. All values were expressed as mean \pm standard deviation (SD). Statistical significance was assessed using paired Student's *t*-test. Values with $p < 0.05$ were accepted as significant.

Results

The effect of different concentrations (10^{-12} – 10^{-6} M) of ipamorelin (IPA) on insulin secretion from pancreatic fragments of normal and diabetic rats is shown in figure 1. IPA evoked large and significant ($p < 0.04$) increases in insulin secretion from the pancreas of normal rats when compared to basal. In normal rat the stimulatory effect of IPA on insulin secretion from the pancreas was maximal at 10^{-9} M and weakest at 10^{-12} M . IPA also induced a large and significant ($p < 0.004$) increases in insulin secretion from the pancreas of diabetic rats at 10^{-9} M . The pancreatic insulin content in normal and diabetic rats was 21.87 ± 1.3 and $3.2 \pm 0.2 \text{ ng ml}^{-1}$ ($100 \text{ mg tissue}^{-1}$), respectively. If the pancreatic insulin contents are compared to the insulin released from the pancreas of both normal [$1.06 \pm 0.1 \text{ ng ml}^{-1}$ ($100 \text{ mg tissue}^{-1}$)] and diabetic [$0.13 \pm 0.01 \text{ ng ml}^{-1}$ ($100 \text{ mg tissue}^{-1}$)] rats after incubation with 10^{-9} M of IPA, it becomes clear that the potency of IPA in stimulating insulin release from the pancreas of normal rat (4.8%) is comparable to that on diabetic rats (4.0%).

The effect of cholinergic, α - and β -adrenergic receptor antagonists on IPA-evoked insulin release is depicted in figure 2. Either yohimbine (α 2-adrenergic receptor antagonist) or propranolol (β -adrenergic antagonist) or diltiazem (calcium channel blocker) or a combination of atropine and yohimbine and propranolol caused a significant ($p < 0.03$) reduction in IPA-induced insulin secretion from the pancreas of normal rats. Atropine induced a small but not significant reduction in IPA-induced insulin secretion from the pancreas of normal rats. It was interesting to observe that,




Figure 1 shows the effect of ipamorelin on insulin secretion from pancreatic tissue fragments of normal and diabetic rats. Basal insulin output is also shown for comparison. (Data are mean \pm SD, n=8). Note that ipamorelin at 10⁻⁹ M evoked a large and significant (p<0.04)* increase in insulin release when compared with basal. In diabetic rat pancreas ipamorelin strongly (p<0.0004)** stimulates insulin secretion when compared with basal.




Figure 2 shows the effect of cholinergic, adrenergic and calcium channel antagonists on ipamorelin (IPA)-evoked insulin release from the pancreas of normal and diabetic rats. (Data are mean \pm SD, n = 8). Note that yohimbine (Yoh) or propranolol (Prop) or diltiazem (Dil) or a combination of atropine (Atr) and yohimbine and propranolol caused a significant (p<0.03) reduction in IPA-induced insulin secretion from the pancreas of normal and diabetic rats. Atropine induced a small but not significant reduction in IPA-induced insulin secretion from the pancreas of normal rats, but it induced a significant (p < 0.007) reduction in IPA-evoked insulin release in diabetic rat pancreas.
 * = p< 0.03 (IPA + antagonist versus IPA alone);
 ** = p< 0.007 (IPA + antagonist versus IPA alone).

either atropine, yohimbine or propranolol or diltiazem or a combination of atropine and yohimbine and propranolol significantly ($p < 0.05$) inhibited IPA-induced insulin release from the pancreas of diabetic rat.

Discussion

The ability of ipamorelin (IPA) to equally stimulate insulin release from the pancreas of both normal and diabetic rats shows that IPA could be of use in the treatment of type II diabetes. IPA may also help in the stimulation of insulin release from diabetic patients with some viable pancreatic beta cells. Since this is the first study to examine the effect of IPA on insulin secretion, it is not possible to compare the results obtained in this study with other reports. However, previous reports have shown that IPA can significantly increase body weight [2, 3] and bone mineral content [4]. The ability of IPA to increase food intake and subsequent weight gain may be exerted through the stimulation of insulin release. The insulin that is released through the action of IPA may in turn stimulate glucose uptake and thus increase the body weight of the subject. The ability of the muscarinic receptor antagonist, atropine, and alpha (yohimbine) and beta (propranolol) adrenergic receptor antagonist to inhibit IPA-induced insulin secretion is interesting. It thus indicates that IPA may act on pancreatic beta cells through muscarinic cholinergic and adrenergic receptors on the cell membrane of pancreatic beta cells. In conclusion, IPA stimulates insulin secretion through a number of pathways including cholinergic and $\alpha 2$ and β -adrenergic receptor pathways and calcium channels.

Acknowledgements

This study was supported by Research Grant # NP/2000/20) from the FMHS, United Arab Emirates University.

REFERENCES

- 1 Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH: Ipamorelin, the first selective growth hormone secretagogue. *Eur J Endocrinol* 1998; **139**:552–61.
- 2 Malmlof K, Johansen PB, Haahr PM, Wilken M, Oxlund H: Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. *Growth Horm IGF Res* 1999; **9**:445–50.
- 3 Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M: Pharmacological characterisation of a new oral GH secretagogue, NN703. *Eur J Endocrinol* 1999; **141**:180–9.
- 4 Svensson J, Lall S, Dickson SL, Bengtsson BA, Romer J, Ahnfelt-Ronne I, Ohlsson C, Jansson JO: The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. *J Endocrinol* 2000; **165**:569–77.
- 5 Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL: Growth Hormone (GH)-Independent Stimulation of Adiposity by GH Secretagogues. *Biochem Biophys Res Commun* 2001; **280**:132–138.
- 6 Andersen NB, Malmlof K, Johansen PB, Andreassen TT, Ortoft G, Oxlund H: The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. *Growth Horm IGF Res*. 2001; **11**:266–272.

- 7 Adeghate E, Ponery AS: Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. *J Neuroendocrinol* 2002; **14**:555–560.
- 8 Adeghate E, Parvez H: Mechanism of ghrelin-evoked glucagon secretion in diabetic rats. *Neuroendocrinol Lett* 2002; **23**:432–436.
- 9 Jimenez-Reina L, Canete R, de la Torre MJ, Bernal G: Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. *Histol Histopathol*. 2002; **17**:707–714.
- 10 Adeghate E: Effect of subcutaneous pancreatic transplantation on streptozotocin-induced diabetes. II. Metabolic and Endocrine parameter. *Tissue Cell* 1999; **31**:66–72.